Explore the words cloud of the OUTLIVE project. It provides you a very rough idea of what is the project "OUTLIVE" about.
The following table provides information about the project.
|Coordinator Country||France [FR]|
|Total cost||3˙563˙750 €|
|EC max contribution||2˙494˙625 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-01-01 to 2021-06-30|
Take a look of project's partnership.
Aortic stenosis (AS) is a life-threatening disease caused by the narrowing of the opening of the aortic valve which is the “gateway” from the heart to the body. With age, the aortic valve calcifies and stiffens, leading to poor blood perfusion. It causes heart failure and sudden death. The only medical response to date consists in replacing the aortic valve. It is provided to very sick patients at high risk of sudden death, who represents 25% of all AS patients (6 million in Europe and US). All other affected patients remain untreated. It is an immense unmet medical need. In this context, French medtech Cardiawave has developed a revolutionary solution: Valvosoft, a very innovative real-time image guided medical device for the non-invasive treatment of all AS patients. The device delivers focused high-intensity ultrasounds which repair the aortic valve function. Unlike the current medical solutions, Valvosoft is a non-invasive treatment with low risks, complications and costs. It is a game-changer for patients, physicians and health care establishments because it dramatically changes the way of treating AS throughout the world. It should become a new gold standard: every AS patients will benefit from Valvosoft. Prize-winner of many contests, Cardiawave was created thanks to the combined expertise of an entrepreneur, the Institut Langevin, world leader in ultrasound imaging & therapy and cardiologists from HEGP hospital. The OUTLIVE project will allow Cardiawave to refine current go-to-market strategy and develop an investor ready business plan following CE-mark. Valvosoft clinical safety and efficacy will be demonstrated and reliable trust relation with early-adopters will be established. OUTLIVE will accelerate the scalable Valvosoft commercialisation and enable Cardiawave to become the future leader in non-invasive therapy with expected cumulative revenues exceeding €1.1bn by 2030 and more than 100 new European jobs created.
|year||authors and title||journal||last update|
D. Suarez Escudero, M. Tanter, M. Pernot
FROM 2D TO 3D REAL-TIME PASSIVE CAVITATION IMAGING OF PULSED CAVITATION ULTRASOUND THERAPY
published pages: , ISSN: , DOI:
M. Pernot, M. C. RÃ©mond, R. Penot, D. LadarrÃ©, Philippe Mateo, N. Ialy-Radio, D. Suarez, Guillaume Goudot, Wojciech Kwiecinski, Michael Vion, F. Betting, AurÃ©lien Corbel, Ana Fouquier, Sergio Cammarata, Eric NoÃ«l, Zahir Larabi, M. Tanter, E. Messas
A new therapeutic device for transthoracic treatment of calcified aortic stenosis
published pages: , ISSN: , DOI:
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OUTLIVE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "OUTLIVE" are provided by the European Opendata Portal: CORDIS opendata.
An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.Read More
IOT and cloud computing for online medical analysis service platformRead More
COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLESRead More